Zacks Research Issues Pessimistic Outlook for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Stock analysts at Zacks Research reduced their Q1 2027 EPS estimates for shares of Prestige Consumer Healthcare in a research note issued on Monday, June 16th. Zacks Research analyst R. Department now expects that the company will earn $1.25 per share for the quarter, down from their previous forecast of $1.26. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q3 2027 earnings at $1.29 EPS.

Several other research firms have also recently weighed in on PBH. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Price Performance

Shares of PBH stock opened at $83.51 on Thursday. The firm has a fifty day moving average of $83.85 and a 200-day moving average of $82.55. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of 19.47, a price-to-earnings-growth ratio of 2.51 and a beta of 0.45. Prestige Consumer Healthcare has a 12-month low of $64.63 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The business had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same quarter in the prior year, the firm posted $1.02 earnings per share. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in PBH. Kestra Investment Management LLC bought a new position in Prestige Consumer Healthcare in the fourth quarter valued at about $27,000. Opal Wealth Advisors LLC acquired a new position in Prestige Consumer Healthcare during the 1st quarter worth approximately $38,000. CIBC Private Wealth Group LLC lifted its stake in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after purchasing an additional 152 shares during the last quarter. Headlands Technologies LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at approximately $40,000. Finally, Geneos Wealth Management Inc. boosted its position in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after buying an additional 269 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.